ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H (HK:1541) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. has announced the successful dosing of the first patient in its Phase Ib clinical trial for IMM0306, a pioneering bispecific antibody aimed at treating neuromyelitis optica spectrum disorder (NMOSD). This innovative treatment targets both CD47 and CD20 to enhance immune response and improve therapeutic outcomes. The company holds global intellectual property and commercial rights to IMM0306, positioning it as a leader in the field of novel biopharmaceutical solutions.
For further insights into HK:1541 stock, check out TipRanks’ Stock Analysis page.